ASCO 2017 | CAR T-cells: an advancement in treating MM?
Gareth John Morgan, MD, FRCP, FRCPath, PhD, from the Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, talks to us about advancements in the treatment of multiple myeloma (MM). He states that although we are in the early days of using CAR T-cells to treat MM, there is particular interest in their use in treating relapsed or refractory B cell maturation antigen (BCMA)-expressing MM and notes a Phase I trial that evaluated this (NCT02786511) and received positive results. He describes that patients in the trial achieved responses even at small doses of the drugs used and that the treatment regimen was safer than expected, which suggests that there is hope for the future for the use of CAR T-cells in treating BCMA-expressing MM. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
